REGULATORY REQUIREMENTS OF ‘SIMILAR BIOLOGICS’ FOR MARKETING AUTHORIZATION IN INDIA
Abstract
Present article signifies the exigency for regulation and regulatory bodies involved in development of biosimilars. The principle for development of biosimilars included opting adequate reference product, manufacturing process optimization, quality control procedure, preclinical and clinical studies. India’s first guidelines were enforced in 2012, with amendments in 2016. Thus, we elaborated the amended guidelines for development of biosimilars.
Downloads
References
2. EMA Guideline on Similar Biological medicinal products containing biotechnology‐derived proteins as active substance: non‐clinical and clinical issues, London: (EMEA/CHMP/BMWP/42832/ 2005 Rev1); 2014.
3. Guideline for Safety Study of Biological Products (KFDA); 2010.
4. World Health Organization (WHO) Guidelines on Evaluation of Similar Bio therapeutic Products (SBP); 2009.
5. GaBI Online. ‘Similar biologics’ approved and marketed in India-Generics and Biosimilars Initiative [Internet]. Generics and Biosimilars Initiative; 2017 [Cited 2016 Feb 3]. Available from:
http://www.gabionline.net/.
6. EMA guideline on Similar Biological medicinal products containing biotechnology derived proteins as active substance: non‐clinical and clinical issues. London: (CHMP/BMWP/42832); 2006.
7. EMA guideline on immunogenicity assessment of biotechnology‐derived therapeutic proteins London: (CHMP/ BMWP/14327); 2007.
8. ICH guideline on preclinical safety evaluation of biotechnology‐derived pharmaceuticals (S6), 1997 and addendum, 2011.
9. RAPS. Biosimilar Medicinal Products: Innovation in Regulatory Review and Approval. [Internet]. RAPS; 2012, Jun [Cited 2016 Feb 3]. Available from:
http://www.raps.org/focus-online/ features/ features-article-view/article/1838/biosimilar-medicinal-products-innovation-in-regulatory-review-and-approval.aspx
10. EMA‐ DNA and Host cell protein impurities routine testing versus validation studies, 1997 X. ICH Q1 A(R2)‐ Stability Testing of New Drug Substances and Products; 2003.
11. World Health Organization (WHO), Guidelines on the quality, safety and efficacy of bio‐therapeutic protein products prepared by recombinant DNA technology; 2013.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
